Immunotherapy

Intrommune Therapeutics Names Sergi X. Trilla, MD, MBA as its Director, Corporate Strategy & Partnerships

Retrieved on: 
Tuesday, December 21, 2021

Dr Trilla will apply the knowledge gained from his experience collaborating on over 160 life science partnerships to oversee corporate strategy, business partnerships and lead Intrommune through our business planning process.

Key Points: 
  • Dr Trilla will apply the knowledge gained from his experience collaborating on over 160 life science partnerships to oversee corporate strategy, business partnerships and lead Intrommune through our business planning process.
  • I am confident that my background as a licensed physician and global entrepreneur distinguishes me as an ideal leader for Intrommune, said Sergi Trilla, MD, MBA, Director of Corporate Strategy & Partnerships, Intrommune.
  • My decades of life science business experience will help advance Intrommune and its OMIT food allergy technology platform.
  • My expertise in international healthcare business also provides a perspective to help Intrommune in its global product and corporate development and partnerships, added Trilla.

Proto Oncogene Protein C-MYC Inhibitors - Global Pipeline Landscape Insight, 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 21, 2021

The "Proto Oncogene Protein C-MYC Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Proto Oncogene Protein C-MYC Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Proto oncogene protein c-myc inhibitors pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Proto oncogene protein c-myc inhibitors R&D.
  • The therapies under development are focused on novel approaches for Proto oncogene protein c-myc inhibitors.

Northwest Biotherapeutics Announces MHRA Approval Of License for GMP Manufacturing At Sawston, UK Facility

Retrieved on: 
Tuesday, December 21, 2021

The MHRA license approval enables the manufacturing of DCVax-L products to get under way at the Sawston facility in addition to continuing at the smaller GMP facility in London.

Key Points: 
  • The MHRA license approval enables the manufacturing of DCVax-L products to get under way at the Sawston facility in addition to continuing at the smaller GMP facility in London.
  • To date, the Company has developed Phase 1A of the facility, comprising approximately 4,400 square feet of the overall 88,345 square feet.
  • This MHRA license is a culmination of intensive preparations that have been underway for much of 2021.
  • This MHRA license follows the license approval by the UK's Human Tissue Authority (HTA) in October.

EXUMA Biotech Completes Series B2 to Advance Novel Cell & Gene Therapies

Retrieved on: 
Tuesday, December 21, 2021

WEST PALM BEACH, Fla., Dec. 21, 2021 /PRNewswire/ -- EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene therapies and delivery solutions for liquid and solid tumors, today announced the completion of a $41 million Series B2 financing.

Key Points: 
  • WEST PALM BEACH, Fla., Dec. 21, 2021 /PRNewswire/ -- EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene therapies and delivery solutions for liquid and solid tumors, today announced the completion of a $41 million Series B2 financing.
  • The Series B2 brings the total capital raised since its inception to approximately $130 million.
  • New investors in the Series B2 financing included Americo Life, Inc., in addition to existing investors.
  • "It's an exciting time for cell and gene therapies.

Galectin Therapeutics Announces Closing of $10 Million in Debt Financing from Its Chairman, Richard E. Uihlein

Retrieved on: 
Tuesday, December 21, 2021

In total, the Company has received $30 million in three convertible notes from Mr. Uihlein in 2021.

Key Points: 
  • In total, the Company has received $30 million in three convertible notes from Mr. Uihlein in 2021.
  • Richard E. Uihlein, Chairman of Galectin Therapeutics, commented, As I have stated many times, I remain deeply committed to the Companys success and our goal of addressing large, unmet medical needs.
  • I am proud of our progress in 2021 and look forward to achievement of additional significant milestones in 2022 and beyond.
  • Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics galectin-3 inhibitor GR-MD-02.

IMV Announces Finalization of the Basket Clinical Study in Collaboration with Merck and Reveals Promising Top Line Data from the Bladder and MSI-High Cohorts

Retrieved on: 
Tuesday, December 21, 2021

The top line clinical data from both the bladder and MSI-Hi cohorts are promising, further showcasing the potential of MVP-S as an immune-educating therapy in multiple cancer indications, said Jeremy Graff, Ph.D., Chief Scientific Officer at IMV.

Key Points: 
  • The top line clinical data from both the bladder and MSI-Hi cohorts are promising, further showcasing the potential of MVP-S as an immune-educating therapy in multiple cancer indications, said Jeremy Graff, Ph.D., Chief Scientific Officer at IMV.
  • A more complete set of data, including evaluation of PD-L1 and other measures will be presented at an upcoming scientific conference.
  • The study was designed to assess primary endpoints of safety and objective response rate (ORR), with multiple secondary and exploratory measures.
  • IMV enrolled 131 patients across clinical sites in the U.S. and Canada.

DBV Technologies Provides Update on Investigational Viaskin™ Peanut

Retrieved on: 
Monday, December 20, 2021

The Company also issued an update on the Marketing Authorization Application for Viaskin Peanut with the European Medicines Agency (EMA).

Key Points: 
  • The Company also issued an update on the Marketing Authorization Application for Viaskin Peanut with the European Medicines Agency (EMA).
  • The study will feature the modified Viaskin Peanut (mVP) patch, which is circular in shape and approximately 50% larger than the current Viaskin Peanut (cVP) patch.
  • DBV is confident that a new, Phase 3 pivotal study generating a robust data set is the best way to support the development of Viaskin Peanut, said Daniel Tasse, Chief Executive Officer, DBV Technologies.
  • DBV Technologies is developing Viaskin, an investigational proprietary technology platform with broad potential applications in immunotherapy.

$8.67 Billion Worldwide Lung Cancer Drugs Industry to 2030 - Identify Growth Segments for Investment - ResearchAndMarkets.com

Retrieved on: 
Monday, December 20, 2021

The lung cancer drugs market consists of sales of lung cancer drugs.

Key Points: 
  • The lung cancer drugs market consists of sales of lung cancer drugs.
  • On the basis of the size of the tumor cells, lung cancer is broadly divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
  • The rising prevalence rate of lung cancer is a major driver for the lung cancer market.
  • This is because chemical lung cancer drugs come with myriads of side effects and have a toxic effect on the body.

Global TIGIT Inhibitor Drug Opportunity & Clinical Research Insight 2022 - ResearchAndMarkets.com

Retrieved on: 
Monday, December 20, 2021

Global TIGIT Inhibitor Drug Opportunity & Clinical Research Insight 2022 Report Highlights:

Key Points: 
  • Global TIGIT Inhibitor Drug Opportunity & Clinical Research Insight 2022 Report Highlights:
    Role of TIGIT Inhibitors in Cancer, HIV, Autoimmune Disorders
    TIGIT Inhibitors Trials By Phase, Company, Country, Indication
    Several pharmaceutical companies have developed a robust pipeline of TIGIT inhibitors in their pipeline indicated for the management of several cancers.
  • Current clinical trials are mainly evaluating the role of TIGIT inhibitors in combination with PD-1/PD-L1 inhibitor or CTLA-4 inhibitors.
  • US will dominate the TIGIT Inhibitor development and commercialization landscape which is mainly attributed to large number of ongoing clinical trials in the region.
  • Beside US, China and South Korea will also emerge as key markets for TIGIT inhibitors drugs driven by increasing research and development activities.

Pfizer and BioNTech to Provide European Union More Than 200 Million Additional Doses of COMIRNATY® to Help Meet Continued Need for Vaccine Supply

Retrieved on: 
Monday, December 20, 2021

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Key Points: 
  • Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
  • For more than 170 years, we have worked to make a difference for all who rely on us.
  • We routinely post information that may be important to investors on our website at www.Pfizer.com .
  • This press release contains forward-looking statements of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995.